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3ABSTRACT 
Heparan sulphate (HS) proteoglycans, composed of a core protein and one or more 
negatively charged HS chains, are a major component of extracellular matrices and 
are located on the plasma membrane of all animal cells. The HS polysaccharide is 
synthesized by alternating addition of glucuronic acid (GlcA) and N-
acetylglycosamine (GlcNAc) from corresponding UDP-sugar precursors. Due to 
subsequent modifications, including epimerization of GlcA to iduronic acid and 
sulphation the resultant polysaccharide is variously sulphate-substituted at different 
positions. Polymerization of HS chains is believed to be catalyzed by the EXT family 
of proteins. In humans, the EXT family consists of five members: EXT1, EXT2, 
EXTL1, EXTL2 and EXTL3. All members of exostoses family harbour in vitro 
glycosyltransferase activities related to HS chain elongation. EXT1-EXT2 form a 
heter-oligomeric complex involved in the chain elongation step in HS biosynthesis, 
but the biological roles of EXTLs are less clearly defined. The aim of the studies 
presented in this thesis was to investigate the roles of the three EXTLs in heparan 
sulphate biosynthesis. Down regulation of EXTL2 or EXTL3 expression in a human 
cell line resulted in increased HS chain length. Also overexpression of EXTL1 or 
EXTL3 resulted in increased chain length. In contrast, overexpression of EXTL2 
resulted in shorter HS chains. The results indicate that these enzymes influence HS 
synthesis and that their expression levels control HS chain length. In addition, all 
three EXTL proteins were able to catalyze the addition of a single GlcNAc to [GlcA-
GlcNAc]n oligosaccharide acceptors, but did not show any detectable transfer of GlcA 
to GlcNAc[GlcA-GlcNAc]n oligosaccharide acceptors. 
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ABBREVIATIONS 
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INTRODUCTION 
Carbohydrates or saccharides are essential components of all living organisms. The 
study of the biosynthesis, structure and function of carbohydrate is referred as 
glycobiology (Rademacher at al., 1988, Rademacher, 1998). Carbohydrates can occur 
as single units (monosaccharides) or as larger structures composed of 2-10 
(oligosaccharides) or more (polysaccharides, glycans) sugar residues. 
Glycoconjugates consists of one or more sugar units covalently attached to a protein 
or a lipid.  Most cells have sugar coating on their surface and sugar chains can make 
an important portion of the glycoconjugates. Cell surfaces associated glycoconjugates 
are mostly attached to the plasma membranes through their protein or lipid moieties. 
Carbohydrates play an important role in protein modifications and in energy 
metabolism and can effect interactions between cells and their surroundings. 
Carbohydrates have complex physical and chemical characters and are often 
heterogeneous both in size and composition (Varki et al., 1999, Schuman et al., 2007). 
In contrast to DNA, RNA and proteins, carbohydrate sequences are not determined by 
reading of a template. Instead carbohydrates are synthesized based upon substrate 
specificity of different glycosyltransferases (Park et al., 2000, Guimond et al., 2001, 
Jones and Vogt, 2001).  
 
PROTEOGLYCANS AND GLYCOSAMINOGLYCANS 
Proteoglycans (PGs) are complex molecules that are composed of a protein core with 
covalently attached long unbranched polysaccharide chains that are called 
glycosaminoglycans (GAGs) (Esko and Selleck, 2002). PGs are classified on the basis 
of the polysaccharide chains or the core proteins. GAGs are linear, and negatively 
charged polysaccharides and are generally grouped into four categories: (1) 
hyaluronic acid or hyaluronan, which occurs as free GAG chains (i.e. not linked to 
core protein), (2) heparin and heparan sulphate (HS), (3) chondroitin sulphate 
(CS)/dermatan sulphate (DS) and (4) keratan sulphate (Figure 1). They are composed 
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of repeating disaccharide units with an N-acetylhexosamine (N-acetylglucosamine or 
N-acetylgalactosamine) as one of the sugar unit. The alternating sugar is glucuronic 
acid (GlcA) with the exception of keratan sulphate that instead contains galactose 
(Lindahl et al., 1998, Sugahara and Kitagawa 2000, Turnbull et al., 2001, Esko and 
Selleck, 2002). 
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Figure 1. Disaccharide repeating structure of different glycosaminoglycans. 
Possible modifications of the basic disaccharide structures are indicated by R=H or 
SO3
- and R'=COCH3, SO3-or H. The glucuronic acid in heparin/HS and CS can be 
epimerised into iduronic acid (indicated by arrows). 
 
HEPARAN SULPHATE/ HEPARIN PROTEOGLYCANS 
Heparin and HS are two closely related GAGs that are synthesized as part of a PG 
(Kjellén and Lindahl, 1991). Heparin was discovered by Mclean in 1916 and was 
found, by mere chance, to inhibit blood coagulation (McLean, 1916). Much later, 
1968, evidence was presented that indicated that the anticoagulant activity of heparin 
was mediated by the plasma protease inhibitor antithrombin (Abildgaard, 1968) but 
actual binding of heparin to antithrombin was first shown in the 1970s by Damus and 
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Rosenberg (Damus et al., 1973). HS was originally discovered as an impurity of 
heparin preparations (Linker at al., 1958) but it has since then become evident that the 
HS chains of a HSPG are involved in many different biological processes. In contrast 
to heparin that occurs exclusively in connective-tissue type mast cells, HS is produced 
by all multicellular organisms from ancient cnidarians to modern mammals, and 
occurs at the cell surface, and in the extracellular matrix (ECM) (Lindahl 2007, 
Lindahl and Li, 2009). Due to the structural heterogeneity of the HS chains, HS 
cannot be considered as a single molecule but rather a family of related molecules and 
heparin can thus be regarded as a highly sulphated variant of HS (Li and Vlodavski 
2009, Lindahl and Li, 2009). HS chain structure is believed to be cell type but not 
core protein specific, so that all HS chains synthesized by a given cell have similar 
structures although they may be linked to different core proteins (Forsberg and 
Kjellén, 2001). Several different PG proteins carry HS chains (Figure 2, Table 1). 
Two of the HS families, the syndecans and glypicans involve HSPGs that are located 
at plasma membrane of cells (reviewed in Bernfield et al., 1999, Kirn-Safran et al., 
2009). Another group of HSPGs are the secreted forms, including perlecan, agrin, and 
collagen XVIII. Serglycin, is an intracellular PG found in haemopietic cells and in 
endothelial cells that, dependent on the cellular origin, carries heparin and/or CS 
chains (Kolset et al., 2004).   
 
Syndecans  
Syndecans are found at cell surface and constitute a family with four members in 
mammals and probably in all vertebrates as well. C. elegans and D. melanogaster has 
only one syndecan (Minniti et al., 2004, Steigemann et al., 2004), while zebrafish has 
three syndecans (syndecan-2, -3, and -4) (Chakravarti and Adams, 2006). Most cells 
and tissues express at least one member of this protein family and many express 
multiple syndecans (Couchman 2003, Yoneda and Couchman, 2003). Vertebrate 
syndecan family are type 1 glycoproteins. Each syndecan has three major domains, a 
large extracellular ectodomain, a short cytoplasmic domain, and a single highly  
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Figure 2. Schematic overview of the main heparin/heparan sulphate 
proteoglycans. 
 
Syndecans and glypicans are both cell membrane associated PGs. Syndecans are 
transmembrane proteins that bears HS chains distal from plasma membrane. Some 
syndecans also carry CS chains close to the plasma membrane. Glypicans are attached 
to cell surface membrane via a GPI anchor and HS chains are located near the plasma 
membrane. Perlecan is an example of an extracellular PG. Serglycin, stored 
intracellular in the secretory granules of connective tissue mast cells, is decorated 
with heparin chains. 
 
 
conserved transmembrane domain (reviewed in Couchman 2003, Xian et al., 2009). 
The extracellular ectodomains are variable in length and sequence between syndecan 
members and contain conserved GAG attachment sites. HS is the principal GAG 
present in all four syndecans and is usually found close to the N-terminus of syndecan 
extracellular domain. Syndecan-1 and syndecan-3 may also carry CS chains close to 
the plasma membrane. The transmembrane domain is important for syndecan dimer 
formation. Dimerization is essential for syndecan-4 dependent activation of protein 
kinase Cα and signalling (Oh et al., 1997, Woods and Couchman 1998, Couchman, 
Cell membrane 
Cytoplasm 
Extracellular matrix 
Syndecans (1-4)   
Glypicans (1-6)  
Perlecan  
Serglycin  
HS 
HS 
HS 
HS 
Heparin 
HS 
HS 
HS 
CS   CS   
GPI anchor 
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2003). The small cytoplasmic domain has two conserved domains, C1 and C2, which 
are hall-marks of the syndecans. Adjacent to the plasma membrane is the C1 domain 
that mediates binding to cytoskeletal proteins (e.g. ezrin) (Granes et al., 2000, Granes 
et al., 2003). The C2 domain that is more distal to the plasma membrane has binding 
sites for PDZ (postsynaptic density 95, disc large ZO-1) domain-containing proteins 
such as syntenin (Grootjans et al., 1997), synbidin (Ethell et al., 2000) and synectin 
(Gao et al., 2000). PDZ proteins have role as scaffolding proteins and in vesicle 
trafficking (Zimmermann et al., 2002, Zimmermann et al., 2005). Between C1 and C2 
is the variable region that is unique to each syndecan and is conserved across the 
species. It is believed that most of the functional difference among syndecans is 
determined by the variable regions (Oh et al., 1997). The variable region of syndecan-
4 binds to phosphatidylinositol 4,5-biphosphate 2 (PIP2) and activates protein kinase 
Cα and is involved in focal adhesion assembly (Oh et al., 1997, Lim et al., 2003). 
Syndecans are widely expressed throughout the development as well as in adulthood, 
and individual family members show cell-tissue and developmental-specific 
Proteoglycans 
Syndecans 1-4 
Core  
protein 
Tissues distribution Number of 
glycosaminoglycane 
 Glypicans 1-6 
  Perlecan 
  Serglycin 
  Agrin 
60 
     31-45 1-3 CS 
1-2 HS   
400  
  10-19 
200 
Membrane bound, epithelial  
cells, cartilage and neuron 
    1-3 HS 
     1-4 HS/CS 
10-15  
Heparin/CS 
1 HS 
1 CS 
Intracellular granules, mast  
cells 
  Betaglycan 
  Collagen XVIII 
 
       110 
       147 
1-3 HS 
 2-3 HS 
        Membrane bound, osteoblasts,    
        skin, spinal cord, glomeruli 
Secreted, basement membrane  
and cartilage 
Secreted, neuromuscular  
junction 
Membrane bound fibroblasts 
  
Secreted, basement membrane 
                                            Table 1. Examples of heparan sulphate proteoglycans 
 Varki et al., 1999. Essentials of Glycobiology, second edition 
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expression (Yoneda and Couchman, 2003). Syndecan-1 is predominantly expressed in 
mesenchymal and epithelial cells and is involved in angiogenesis, wound healing and 
leukocyte-endothelial interactions (Woods and Couchman 2001, Couchman et al., 
2001). Syndecan-2 is expressed in vasculature, particularly during embryogenesis 
(Chen et al., 2004). Reduction of syndecan-2 levels in mouse brain microvascular 
results in decreased capillary tube formation (Fears et al., 2006). In Xenopus laevis, 
syndecan-2 expression in the ectoderm is required for normal left-right axis that is 
necessary for asymmetric placement of the developing heart (Kramer and Yost, 2002). 
Syndecan-3 is mainly found in neural tissue and cartilage (Alexander et al., 2000). 
Syndecan-3 knock mice are resistant to diet-induced obesity (Strader et al., 2004) and 
show neural migration defects in brain (Hienola et al., 2006). Syndecan-4 is widely 
expressed through all stages of embryonic development but has restricted expression 
in adult (Woods and Couchman 1994, Woods and Couchman 2001, Zhang et al., 
2003). Syndecan-4 deficient mice show delayed wound healing and impaired 
angiogenesis (Echtermeyer et al., 2001). 
                      Syndecans can be shed from the cell surface by the action of proteases 
(Endo et al., 2003). Shedding of syndecan-1 ectodomain has been shown to regulate 
cell movements suggesting that the shed ectodomain may convey motility signals 
distinct from the cell surface bound form. Upon release of the ectodomain, the 
intracellular domain can signal independently or may be degraded. In wound healing, 
increased levels of syndecan-1 and syndecan-4 are shed into wound fluids (Tumova et 
al., 2000, Endo et al., 2003).  
 
 
Glypicans  
HSPGs also attach to the cell surface by a family of glycosylphosphatidylinositol 
(GPI) anchored core proteins called glypicans (reviewed in Bernfield et al., 1999, 
Kramer and Yost 2003, Filmus et al., 2008). Their protein core consists of a N-
terminal signal peptide, a cystein rich globular ectodomain, and a hydrophobic 
cytoplasmic domain that is involved in the formation of the GPI anchor. The 
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cytoplasmic domain contains three to four attachment sites for HS close to the cell 
surface. Six glypicans have been characterized in human and mouse (glypican 1-6), 
two in Nematostella vectensis, five in zebrafish and two in D. melanogaster (De Cat 
and David 2001, Filmus et al., 2008). During embryonic development glypican-1 is 
expressed in skeletal muscles, osteoblasts, skin, and the glomeruli (Litwack et al., 
1998). In the adult, glypican-1 is expressed in most tissues (David et al., 1990, 
Litwack et al., 1998). Glypican-2 occurs specifically in developing brain, especially 
located to the spinal cord and dorsal root ganglia and appears not to be present in 
adults (Ivins et al., 1997). Glypican-3, -4, -5, and -6 is found in most tissues during 
embryonic development while their expression is more restricted in adult animals. 
Glypican-3 is so far the only cell surface HSPG core protein that has been linked to a 
human disease. The X-linked human overgrowth syndrome, Simpson-Golabi-Behmel 
disorder, is caused by mutation in glypican-3 gene (Pilia et al., 1996). This disease is 
characterized by tissue and organ overgrowth, macroglossia, congenital defects and 
an increase risk for developing various tumours. The glypican-3 deficient mice 
resemble several of the clinical findings of the human patients such as development 
overgrowth, dysplastic kidneys and abnormal lung development (Pellegrini et al., 
1998, Filmus, 2001). 
                    Glypicans can be proteolytically cleaved near the centre of the core 
protein by a furin-like convertase (De Cat et al., 2003, Fransson et al., 2004). The GPI 
anchor can be cleaved by phospholipases or by proteases, which causes shedding of 
glypican ectodomain from the cell surface (David et al., 1990, Lugemwa and Esko 
1991, Traister et al., 2008). In D. melanogaster the shed glypicans play a role in 
morphogen gradient formation (Fujise et al., 2003, Han et al., 2004).  
 
 
Extracellular matrix heparan sulphate proteoglycans 
The major secreted HSPG species are perlecan (Knox and Whitelock, 2006), collagen 
XVIII and agrin present in the ECM (Iozzo, 2005). Perlecan core protein contains 
four potential GAG attachment sites for HS and CS, whereas agrin has three GAG 
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attachment sites for HS (Bezakova and Ruegg 2003, Knox and Whitelock, 2006). 
Agrin is primary considered a neural PG and recognised as a key player in formation, 
maintenance and regeneration of neuromuscular junction (Prydz and Dalen 2000, 
Bezakova and Ruegg, 2003). Collagen XVIII expressed in the basement membrane of 
mouse and human tissues carries HS chains (  	 
 ., 1997, Iozzo, 2005). 
Endostatin, the C-terminal of collagen XVIII, contains anti-angiogenic properties and 
treatment with endostatin can reduce tumour growth by interfering with tumour 
angiogenesis (	
., 1997, Abdollahi et al., 2004). 
 
Serglycin 
Serglycin is found in haemopietic cells and in endothelial cells. In the secretory 
granules of connective tissue mast cells, serglycin is substituted with the highly 
negatively charged heparin (Kolset et al., 2004). Serglycin knock out mice develop 
normally, but the mast cells have fewer secretory granules and reduced amounts of 
histamine (Abrink et al., 2004, Niemann et al., 2007), indicating that serglycin is 
involved in generation of storage granules in mast cells.  
 
BIOSYNTHESIS OF HEPARAN SULPHATE  
HS biosynthesis is carried out by a complex enzymatic machinery involving many 
different enzymes. Most GAGs attached to a protein share a common multistep 
biosynthetic process (reviewed in Lindahl et al., 1998, Esko and Lindahl 2001, Esko 
and Selleck, 2002). This process involves a series of glycosyltransferases in the Golgi 
compartment transferring nucleotide sugars to oligo- or polysaccharides or proteins 
and sulfotransferases utilizing 3'-phosphoadenosine-5'-phosphosulphate (PAPS) as 
sulphate donor. PAPS similar to nucleotide sugars is synthesized in the cytoplasm and 
imported into endoplasmic reticulum by specific transporter proteins (Hirschberg et 
al., 1998, Dick et al., 2008). HS chains synthesis is initiated by the formation of a 
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tetrasaccharide linker attached to a selected serine residue in the core protein. After 
that, chain elongation proceeds by sequential addition of GlcA and N-acetyl 
glucosamine (GlcNAc) residues. During chain elongation, HS chains undergo 
extensive modifications including sulphation and epimerization, resulting in variety of 
structurally diverse HS chains (Lindahl et al., 1998, Bernfield et al., 1999, Esko and 
Selleck, 2002) (Figure 3). The regulation of this process, as required to generate 
specific HS structures, is poorly understood, but apparently involves arrays of enzyme 
isoforms that differ with regard to substrate specificities and kinetic properties. 
 
Formation of linkage region and heparan sulphate chain assembly    
Linkage region formation is initiated by the transfer of xylose from uridine-5-
diphoshate (UDP)-xylose to a specific serine residue in the core protein (Zhang and 
Esko 1995, Sugahara and Kitagawa, 2002). This reaction is followed by addition of 
two galactose residues and the so-called GAG-protein tetrasaccharide linkage is 
completed by addition of GlcA (Sugahara and Kitagawa 2000, Bishop et al., 2007). 
These reactions are catalysed by specific glycosyltransferases. The tetrasaccharide 
linkage is common for PGs carrying glucosaminoglycans (heparin and HS) and 
galactosaminoglycans (CS and DS) (Esko and Selleck, 2002). Addition of the 
subsequent sugar unit to the tetrasaccharide linker determines the type of GAG chain 
that will be synthesized (Esko and Zhang 1996, Pyrdz and Dallen, 2000). If a GlcNAc 
is added HS or heparin is synthesised but if instead, N-acetylgalactosamine is added, 
it leads to the synthesis of CS/DS. The exact mechanism that determines whether HS 
or CS/DS will be synthesized is not known but it is generally believed that it depends 
on enzyme recognition of the PG polypeptide (Esko and Zhang 1996, Chen and 
Lander, 2001). Acidic as well as hydrophobic repetitive ser-gly sequence on the core 
protein facilitates GlcNAc attachment and the formation of HS/heparin (Lugemwa 
and Esko 1991, Zhang and Esko, 1994) while biosynthesis of CS/DS occurs when 
numbers of acidic amino acid residues, surrounding the ser-gly sequences are reduced 
(Esko and Zhang, 1996). However, none of the described sequences explains the 
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mechanism that determines whether a protein is turned into a heparin/HSPG or into 
another type of PG as the same core protein may carry either HS or CS in various 
tissues. 
                     Addition of the first GlcNAc is believed to be catalyzed by EXTL 
(Exostosin Like) enzymes which are member of the exostosin (EXT) enzyme family 
(Kim et al., 2001, Zak et al., 2002, Sugahara and Kitagawa 2002, Busse et al., 2007). 
Following the addition of the GlcNAc, polymerisation of HS by alternating additions 
of GlcA and GlcNAc to the non-reducing end of the chain is carried out by a complex 
of two other proteins of the EXT-family, EXT1 and EXT2 (Senay et al., 2000, 
McCormick et al., 2000). (The EXT-family is described more in detail below). 
 
Heparan sulphate chain modification reactions  
As the chain polymerizes, it undergoes a series of modification reactions that include 
N-deacetylation followed by N-sulphation of glucosamine residues, epimerization of 
GlcA to iduronic acid (IdoA) and finally O-sulphation at various positions (Kjellén 
and Lindahl 1991, Esko and Lindahl, 2001). The extent of these reactions varies, 
giving rise to enormous structural heterogeneity of HS chains. The first modification, 
N-deacetylation followed by N-sulphation of glucosamine units, has a key regulatory 
role in determining the overall structure and charge density of HS, as N-sulphation of 
glucosamine units is required for all subsequent modifications. The first modification 
is catalysed by one or more of the four N-deacetylase/N-sulfotransferase (NDST) 
isoenzymes (NDST1-4). These enzymes have dual action; removal of N-acetyl groups 
from GlcNAc residues generating GlcNH3+ followed by the sulphation of generated 
free amino groups (Lindahl et al., 1998, Grobe and Esko, 2002). The central role of 
the NDST enzymes in polymer modifications is due to that substrate recognition 
requirements of subsequent modification enzymes. Further modifications of HS 
chains, such as GlcA C5-epimerisation and O-sulphation reactions, are concentrated 
around the regions of N-sulphated (NS) GlcN residues (Lindahl et al., 1998,  
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Figure 3. Schematic overview of heparan sulphate biosynthesis. 
 
HS biosynthesis is initiated by addition of xylose to serine residue in core protein. 
This is followed by the sequentional addition of two galactose residues and a GlcA 
residue, thus forming the tetrasaccharide linker. The transfer of a single GlcNAc unit 
to the tetrasaccharide linker is catalyzed by GlcNAc transferase-I, possibly 
represented by EXTL3. The role EXTL1 and EXTL2 in HS biosynthesis is not clearly 
defined. Enzyme complex of EXT1 and EXT2 elongates the chain by alternate 
addition of GlcA and GlcNAc residues. Further enzymatic modifications in HS chains 
include N-deacetylation and N-sulphation of GlcNAc residues, epimerization of GlcA 
to IdoA and various O-sulphations. Outside the cells, HS chains are further modified 
by SULF1 and SULF2 that remove 6-O-sulphate groups from selected glucosamine 
units (not shown). 
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Gallagher et al., 2001, Esko and Selleck, 2002). Inactivation of NDST-1 in mice 
cause severe brain, facial and eye defects (Grobe et al., 2005), together with skeletal  
abnormalities (Pallerla et al., 2007). The mutant mice die due to respiratory failure 
(Ringvall et al., 2000, Forsberg and n, 2001). Mice lacking NDST-2, are fertile 
with a normal life span and normal HS structure but have defect in connective tissue 
mast cell morphology and lack sulphated heparin (Forsberg et al., 1999, Ledin et al., 
2004). Epimerisation of GlcA into IdoA is catalysed by the enzyme glucuronyl C5-
epimerase (Jacobsson et al., 1984, Li et al., 1997). Inactivation of epimerase results in 
synthesis of HS containing GlcA but no IdoA. Epimerase mutant mice show renal 
agenesis, skeletal malformations and immature lungs and the mutants die from 
respiratory failure (Li et al., 2003). The 2-O-sulfotransferase (2OST) transfers 
sulphate to both IdoA and GlcA residues, with a strong preference for sulphate 
transfer to IdoA (Rong et al., 2000, Rong et al., 2001). 2OST deficient mice show 
renal agenesis and die in the neonatal period. These mice also have eye and skeletal 
abnormalities (Bullock et al., 1998, Forsberg and n, 2001). The HS chains from 
2OST deficient cells have large NS domains containing IdoA with no 2-O sulphation 
but with increased 6-O sulphation. Except for the presence of IdoA, these chains 
structurally resemble the HS from the C5-epimerase deficient mice, suggesting that 2-
O-sulphation of IdoA is necessary for proper kidney development (Kamimura et al., 
2001, Merry et al., 2001). 6-O-sulphation and 3-O-sulphation of glucosamine units 
are performed by the respective O-sulfotransferases (OSTs) (Liu et al., 1999, Smeds 
et al., 2003). Three HS 6-O-sulfotransferas (6OST1-3) are known (Habuchi et al., 
2003). Disruption of the single 6OST in D. Melanogaster is embryonic lethal 
(Kamimura et al., 2001). Mice lacking 6OST-1 have defects in control of axon 
movements indicating that 6OST-1 has an important role in mammalian axons 
development (Pratt et al., 2006). 6OST-2 knock out embryos show abnormal muscle 
phenotype (Bink et al., 2003). HS 3-O-sulphation of glucosamine units is the last 
modification reaction carried out by 3OSTs (Liu et al., 1999). 3OSTs have seven 
isoforms in mammals (3OST1, 2, 3A, 3B, 4, 5 and 6) (Shworak et al., 1999, Xia et al., 
2002). Heparin is used clinically as an anticoagulant and this activity is mediated by 
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the binding of a unique pentasaccharide sequence in heparin to the protease inhibitor 
antithrombin. 3-O-sulphation is essential for the interaction of heparin and HS with 
antithrombin, however mice lacking 3-OST-1 do not show a procoagulant phenotype 
despite reduction in level of antithrombin binding HS (HajMohammadi et al., 2003). 
                    Once the synthesis of HSPG is completed it is transported from the Golgi 
apparatus to ECM or to the cell surface (Bishop et al., 2007). At the cell surface, the 
HS chains are further modified by HS 6-O-endosulfatases (SULFs: SULF1 and 
SULF2). SULFs are associated with the plasma membrane and modify HS chain by 
removing 6-O-sulphate groups from glucosamine units (Ai et al., 2003, Ai et al., 
2006).  Removal of 6-O-sulphates has a major effect on HS-binding ligands and cell 
signalling pathways (Dhoot et al., 2001, Ai et al., 2003). For example, fibroblast 
growth factor (FGF) signalling requires HS-6-O-sulphate groups to form a functional 
HS/FGF/FGF-receptor signalling complex (Schlessinger et al., 2000). SULF1 or 
SULF2 mutant mice appear normal but double mutant mice show delayed myogenic 
differentiation and regeneration (Langsdorf et al., 2007). Each cell in our body 
synthesises HS chains of different structure and of different length. The molecular 
diversity of HS is due to the incomplete action of HS enzymes involved in the HS 
modification reactions and remodelling of HS sulphation pattern at the cell surface by 
SULFs (Dhoot et al., 2001, Ai et al., 2003).  
                    The mature HS chain is heterogeneous in nature and is composed of three 
different domain structures, these are unmodified non-sulphated N-acetylated (NA) 
regions with GlcA residues, contiguous NS regions that are 2-O- and 6-O-sulphated 
and contain both GlcA and IdoA units, and mixed sequences of alternating NS and 
NA disaccharide units. The mixed sequences, like the NS domains, contain GlcA, 
IdoA and 6-O-sulphated residues, but lack 2-O-sulphate groups (Turnbull and 
Gallagher 1991, Maccarana et al., 1996, Murphy et al., 2004).  
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THE EXOSTOSIN FAMILY 
There are five members of the exostosin (EXT) family in humans (Table 2); EXT1, 
EXT2, EXTL1, EXTL2 an EXTL3. All members of the EXT family are type II 
transmembrane proteins with a short amino terminal cytoplasmic tail, a 
transmembrane domain, stem region and a large catalytic domain (McCormick et al., 
1998, McCormick et al., 2000, Pedersen et al., 2003) (Figure 4). All EXTs contain at 
least one aspartic acid-any amino acid-aspartic acid (DXD) motif critical for binding 
UDP-sugars that is shared by most glycosyltransferases (Pedersen et al., 2003). The 
EXT amino acid sequences are most similar in their C-terminal regions (Nadanaka 
and Kitagawa, 2008). 
EXT1 and EXT2
In vitro studies have shown that EXT1 have both GlcNAc-transferase and GlcA-
transferase activity and is able to polymerize HS on oligosaccharide substrates, 
whereas EXT2 only adds a single GlcA without further elongation (Busse and 
Kusche-Gullberg 2003, Kim et al., 2003). The physiological active chain elongation 
unit is generally believed to be a hetero-complex of EXT1/EXT2. Such hetero-
complex has increased transferase activities compared to the activities observed for 
EXT1 or EXT2 alone (McCormick et al. 2000, Senay et al. 2000). EXT1 and EXT2 
mutants fail to undergo gastrulation and are embryonic lethal (Lin et al., 2000, Lin et 
al., 2004, Stickens et al., 2005). siRNA silencing of EXT1 or EXT2 results in 
synthesis of shorter HS chains (Busse et al., 2007). EXT genes are well conserved 
between human, D. melanogaster and C. elegans and are essential in the biosynthesis 
of HS (Clines et al., 1997, Bellaiche et al., 1998). ttv (tout-velu) is the ortholog of 
EXT1 and sotv (sister of tout-velu) is the ortholog of EXT2 in D. melanogaster
(Bellaiche et al., 1998). Mutations in sotv and ttv lead to defective HS biosynthesis, 
impaired hadgehog, wingless, Decapentaplegic signalling and morphogen distribution  
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Figure 4. Typical topology of type II transmembrane glycosyltransferases. 
 
Golgi glycosyltransferases and sulfotransferases generally have a single hydrophobic 
transmembrane (TM) domain flanked by a short amino-terminal domain and a large 
catalytic C-terminal region. This topology places the catalytic domain of a 
glycosyltransferase within the lumen of the Golgi apparatus. 
 
 
(Bellaiche et al, 1998, Takei et al., 2004) (Table 2). rib-1 and rib-2 are homologous to 
mammalian EXT1 and EXTL3 respectively in C. elegans (Clines et al., 1997). rib-1 is 
required for HS biosynthesis and during embryonic morphogenesis in C. elegans. rib-
1 knockout mutants show reduction in HS biosynthesis and embryonic lethality 
(Kitagawa et al., 2007). Coexpression of rib-1 and rib-2 results in increased 
glycosyltransferase and polymerase activities (Kitagawa et al., 2007). 
Catalytic  
domain 
Stem 
Golgi lumen 
  Cytoplasm 
Golgi membrane 
NH2 
T 
M 
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                                                                         (Table modified from Hul et al., 1998) 
EXTL1 
EXTL1 is more closely related to EXT1 than the other EXT members (Freeman and 
Gurdon, 2002). EXTL1 is found in all investigated mammals but not in lower 
vertebrates. Human EXTL1 is expressed in limited areas such as skeletal muscles, 
brain and heart (Wise et al., 1997). In adult mouse, EXTL1 is strongly expressed in    
liver, skeletal muscles, brain and heart (Stickens et al., 2000). The more restricted 
expression of EXTL1 may suggest a more specialized function. It has been shown by 
in vitro studies that EXTL1 adds GlcNAc to the non-reducing end of growing HS 
chain (GlcNAc transferase-II activity) (Kim et al. 2001, Kim et al. 2002, Kim et al., 
2003). No mutants of EXTL1 are described yet. Precise role of EXTL1 in the 
regulation of HS chain is not known. 
 
EXTL2 
Similar to EXTL1, EXTL2 is found in all investigated mammals but not in lower 
vertebrates. EXTL2 is the shortest member of the EXT family consisting of 330 
Kitagawa et al., 1999 
Protein 
EXT1 
Molecular  
weight kD 
Number of 
amino acid  
Expression  
pattern 
Chromosome 
localisation 
 
 EXT2 
  EXTL1 
  EXTL2 
  EXTL3 
 86 
718 
 75 
746 
38 
105 
Chr.8 q24.11  
 
676  
330 
919 
 82 
ubiquitous 
   Chr.11 p11.2 
    Chr.1 p36.11 
Chr.1 p21.2 
Chr.8 p21.1 
ubiquitous 
brain, liver,  
muscles  
ubiquitous 
ubiquitous 
Reference 
Wise et al., 1997 
 Hul et al., 1998 
Wu et al., 1994 
    Wuys et al., 1995 
Cook et al., 1993  
                                Table 2. Properties of five human EXTs 
    Wise et al., 1997 
     Hul et al., 1998 
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amino acids (Pedersen et al., 2003). EXTL2 is located at chromosome 1p21 which is 
the region involved in many chromosomal rearrangements in many tumours (Wuyts et 
al., 1997).  EXTL2 is ubiquitously expressed in all human tissues. Phylogenetic 
analyses of EXT gene family based on amino acid sequences alignments show that 
EXTL2 is the most divergent, indicating that it was the first gene to evolve separately 
from the other EXT family members from a common ancestor (Hul et al., 1998). 
EXTL2 has shown to have GlcNAc-TI activity in vitro i.e. adds the first GlcNAc unit 
to the GlcA in the polysaccharide protein-linkage region (GlcA-Gal-Gal-Xyl-O-Ser) 
(Kim et al., 2001, Sugahara and Kitagawa, 2002). EXTL2 also transfers N-
acetylgalactosamine to the linkage region in vitro (Kitagawa et al., 1999, Pedersen et 
al., 2003). Mouse EXTL2 is the only member of EXT gene family to be crystallized 
as ternary complex with UDP and the acceptor substrate (Pedersen et al., 2003). The 
structure shows three highly conserved residues in EXTL2 which are located at the 
active binding site of EXTL2 and play important roles in glycosyltransferase activity 
of catalytic globular domain by correctly positioning the substrate for the binding. 
This domain catalyzes both UDP-GalNAc and UDP-GlcNAc transferase activities 
and mutations in this region reduce the EXTL2 catalytic activity. The two subdomains 
of the catalytic domains, described as UDP-sugar- binding domain and acceptor 
binding domain are connected with loop and contain the conserved DXD motif. DXD 
motif provides the main binding element for catalytic metal Mn+2 ions and UDP-sugar 
donor and helps in keeping them into correct place and orientation and coordinates for 
catalytic activity by inducing conformational changes in the active binding site. 
(Pedersen et al., 2003, Negishi et al., 2003). However, the primary function of EXTL2 
in vivo is not clear yet. 
 
EXTL3    
In contrast to the other two EXTLs, EXTL3 is expressed in all investigated species 
from sea anemones to humans. EXTL3 is ubiquitously expressed in human tissues in 
both embryonic and adult lives (Wise et al., 1997, Saito et al., 1998, Litwack et al., 
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1998). EXTL3 has a role in brain development and corticogensis in mouse embryo, 
and in adult mice in the apical dendrite of pyramidal neurons (Litwack et al., 1998, 
Osman et al., 2004). In vitro analyses indicate that EXTL3 has both GlcNAc 
transferase-I and GlcNAc transferase-II activities and thus may be involved in the 
initiation and/or elongation of HS chain (Kim et al., 2001, Kim et al. 2002, Kim et al. 
2003, Takahashi et al., 2009). Human EXTL3, rib-2 and botv (brother of tout-velu, 
EXTL3 ortholog in D. Melanogaster) share high amino acid sequence homology 
especially in C-terminal parts. rib-2 has, similar to the human counterpart, both 
GlcNAc transferase-I and transferase-II activities. rib-2 mutants show developmental 
delay and egg laying defects due to defective HS biosynthesis (Kitagawa et al ., 2001, 
Morio et al., 2003, Nadanaka and Kitagawa, 2008). HS levels are reduced in botv 
mutants and this results in severely impaired signalling (Tumova et al., 2000, Kim et 
al., 2001, Bornemann et al., 2004, Takei et al., 2004).  
                    EXTL3 has been suggested to be the receptor for pancreatic -cell 
regenerating (Reg) protein in humans and in rats (Kobayashi et al., 2000, Okamoto 
and Takasawa, 2002). -cell specific EXTL3 knock out mice are embryonic lethal  
and die around embryonic day 9 and lack HS-derived disaccharide confirming the loss 
of EXTL3 in -cell results in marked defective HS biosynthesis. Thus, EXTL3 
appears to be essential for HS biosynthesis in these -cell specific EXTL3 knock out 
mice and the other EXT members can not compensate for this loss of EXTL3 
(Takahashi et al., 2009). Previous results from our lab indicate that the cells 
transfected with siRNA against EXTL3 have longer HS chains as compared to control 
chains and it was speculated that siRNA treatment of EXTL3 results in the synthesis 
of fewer linkage region containing the first GlcNAc for elongation of HS chain and 
thus there is more extensive polymerisation of the HS chains that are synthesized 
(Busse et al., 2007). In a recent paper by Okada and colleagues it was shown that 
knockout of EXTL3 in EXT1 defective cells had little effect on the biosynthesis of 
HS (Okada et al., 2010). In the paper it was speculated that EXTL3 may have a role in 
regulating the number and length of HS chains and not be necessary for HS chain 
elongation (Okada et al., 2010). 
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HEREDITARY MULTIPLE OSTEOCHONDROMA 
Hereditary Multiple Osteochondromas (MO) or Hereditary Multiple Exostoses is an 
autosomal dominant human disorder linked to mutations in EXT1 and EXT2 (Wuyts 
and Hul, 2000). MO affects 1:50 000 of the population and usually develops before 
the age of 10 (Schmale et al., 1994). MO is characterized by cartilage capped bony 
outgrowths at the end of long bones (Solomon 1963, Ahn et al., 1995, Wuyts et al., 
1996). Common complications are short stature and skeletal deformities (Solomon et 
al., 1963, Hennekam 1991, Stieber and Dormans, 2005). There are 1-2% risks of 
malignant transformation of MO into chondrosarcoma (Solomon et al., 1963, Schmale 
et al., 1994). Endochondral bone growth is a strictly regulated process, taking place in 
the growth plate in which proliferating chondrocytes pass different stages of 
proliferation and differentiation until they constitute a scaffold for invading 
osteoblasts. Histologically the chondrocytes are discernable in columnar structures 
with the direction of differentiation towards the diaphysis. Chondrocyte morphology 
of an exostose resembles growth plate columnar histology, but is highly disorganised 
and HS production is severely reduced (Hecht et al., 2002). In the growth plate, HS is 
involved in regulation of chondrocyte differentiation and proliferation through Indian 
Hedgehog/parathyroid hormone like hormone and FGF signalling (Vortkamp et al., 
1996, Cormier et al., 2002). One theory on the aetiology of MO is that mutations in 
EXT1 or EXT2 result in decreased HS formation which reduces Indian 
Hedgehog/parathyroid hormone like hormone and FGF signalling. This results in 
abnormal chondrocyte proliferation leading to exostoses (Kroneberg 2003, Koziel et 
al., 2004). Mutations in EXTLs have so far not been linked to MO (Kitagawa et al., 
1999).  
HEPARAN SULPHATE FUNCTIONS  
HS chains bind to a large number of ligands such as growth factors and their 
receptors, morphogens, plasma proteins and basement membrane components 
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(Rapraeger et al., 1991, Huntington 2003, Bishop et al., 2007). The binding of HS to 
proteins has important physiological functions by influencing many cellular processes 
such as embryonic development, morphogen distribution, intracellular signalling, 
angiogenesis and cell adhesion (Figure 5) (Huntington 2003, Kramer and Yost 2003, 
 
 
 Selleck 2006, Bishop et al., 2007, Kirkpatrick and Selleck, 2007). HSPGs biological 
functions usually involve one or more HS chains. The linear and sulphate substituted 
HS chains contribute to selective protein binding through highly specific saccharide 
sequence motifs in the HS chains (Spillman and Lindahl 1994, Turnbull et al., 2001). 
HS can modulate protein function in many different ways. The mechanisms by which 
HS modulates the signalling activity of several growth factors include growth factor 
receptor dimerizations, receptor ligand complex stabilisation, reducing the 
dimensionality and cellular transport of ligands. In dimensional sliding contact, HS 
chain reduce the dimensionality of the molecule and allow more frequent encounter 
with the high affinity signalling receptor molecules which are present in less 
quantities and can trigger a biological response by forming complexes with the 
 
Protein 
rib-1 
sotv 
ttv 
botv 
GlcNAcT-I GlcNAcT-II Phenotype GlcAT-1 
 
 - - - Developmental defects in embryo  
 -  +  + Defect in Hh, Dpp signalling 
    
mEXT1  -  +  + Disruption of gastrulation 
hEXT1  -  +  + Exostoses 
hEXTL3     +  +  - ? 
hEXTL2     +  -  -    ? 
rib-2 
mEXT2  -       +        +     Disruption of gastrulation 
 -  +  + Defect in Hh and Dpp signalling 
mEXTL1     NT  NT  NT  ?  
mEXTL2     +  -  - 
hEXT2  -  +  + Exostoses 
    +  +  - Developmental defects in embryo 
mEXTL3     NT  NT  NT Embryonic lethal at E10.5 
    +  +  - Defect in Hh, Dpp signalling 
References 
 Kitagawa et al., 2007 
                        Han et al., 2004 
        Kitagawa et al., 2001 
   - = no activity        NT = not tested   m=mouse   h=human   Hh= Hedgehog   Dpp=Decapetaplegic                             
  Han and Takei et al., 2004 
Lin et al., 2000 
 Stickens et al., 2005 
 McCormick et al., 2000 
McCormick et al., 2000 
 Kitagawa et al., 1999 
hEXTL1  -  +  - ? Kim et al., 2001 
 Kim et al., 2001 
Bellaiche et., 1998 
 Takahashi et al., 2009 
 Kitagawa et al., 1999 
Table 3. Glycosyltransferase activities of EXTs 
    rib-1 and rib-2= EXT1 and EXTL3 ortholog in C. 
            ? 
 botv=brother of tout-velu, EXTL3 ortholog in D. melanogaster  
 sotv= sister of tout-velu, EXT2 ortholog in D. melanogaster         
                       (Table modified from Nadanaka and Kitagawa, 2008)    
  
31 
molecules (Baeg et al., 2001). In transcellular mechanism, molecules reach remotely 
placed cells by moving through neighbouring cells using HS (Nybakken and 
Perrimon, 2002). One of the most studied HS ligand is FGF-2. FGF is a family of 
secreted proteins produced by variety of cells and is important during organogenesis 
and in adult life (Ornitz and Itoh, 2001). Binding of FGFs to their tyrosine kinase 
signalling receptors (FGFRs) requires HS (Rapraeger et al., 1991, Nurcombe et al., 
1993, Schlessinger et al., 2000). The FGF-FGF-receptor complex stabilizes and 
protects FGF molecules against inactivation and results in prolonged transmembrane 
signalling and biological response (Nurcombe et al., 1993). 
                    The plasma proteinase inhibitor antithrombin inhibits serine proteases 
involved in blood coagulation (Bjork and Lindahl 1982, Dahlback, 2000). In presence 
of heparin, the rate of inactivation is greatly increased (Rosenberg et al., 1977, 
Rostand and Esko, 1997). This is due to that heparin binding induces a 
conformational change in antithrombin. High affinity for antithrombin is mediated by 
a specific pentasaccharide sequence in heparin (Lindahl et al., 1980, Lindahl et al., 
1984). 
                     Lipoprotein lipase mediated binding of lipoprotein to HS serves an 
important biological function. HS binding at cell surface and in the ECM brings 
lipoprotein close to cell surface to facilitate its metabolic processes that occur at the 
cell surface (Eisenberg et al., 1992). Liver HS can act as a triglyceride rich 
lipoproteins clearance receptor. Syndecan-1 facilitates lipoprotein uptake and 
degradation in liver hepatocytes (Fuki et al., 1997, Mahley and Ji 1999, Bishop et al., 
2008, Stanford et al., 2009). Syndecan-1 is the primary hepatocyte HSPG receptor in 
mice which mediates the clearance of both intestinal and hepatic derived triglyceride 
rich lipoproteins in vivo. Syndecan-1 knock out mice show delayed triglyceride 
clearance from dietary fat and accumulate triglyceride rich lipoproteins (Stanford et 
al., 2009).  
                    HS chains can act as coreceptor for herpes simplex virus and Neisseria 
gonorrhoeae (Rostand and Esko 1997, Dehioa et al., 1998). Removal of HS at cell                    
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Figure 5. Heparan sulphate proteoglycans function. 
 
(1, 2) HS presents growth factors to their receptor on the same cell or adjacent cell to 
form signalling complex. (3, 4) HS may transport chemokines across the cell and 
presents at the cell surface. (5) Proteolytic shed and (6) heparanase cleavage of HS 
chains can release HS bound ligands. (7) HS facilitates cell-adhesion and (8) forms 
bridges to the cytoskeleton. (9)  Serglycin carrying heparin chains is required for 
storage of protease and histamine in secretory granules of mast cells.  
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surface reduces the invasion of the pathogens (Sawitzky et al., 1996, Summerford et 
al., 1998).        
                    Cancer is associated with changes in cell morphology and loss of 
differentiation and uncontrolled proliferation of cells followed by tissue invasion and 
metastasis (Cho and Fearon, 1995). Many of these processes involve HS. Syndecan-1 
is one important determinant of cellular differentiation and has an important role in 
maintaining normal cell morphology (Mali et al., 1994, Kato et al., 1995, Sanderson 
and Borset, 2002). Transformation of epithelial cells is associated with loss of 
syndecan-1 expression in many poorly differentiated carcinomas of head, neck, lung 
and cervix (Inki et al., 1994, Inki et al., 1996). Syndecan-1 shedding from the 
myeloma cells can induce apoptosis of the myeloma cells in vitro and thus decrease 
the invasiveness of the tumour (Dhodapkar et al., 1998). Glypican-1 expression is
upregulated in pancreatic tumours (Kleef et al., 1998). Glypican-3 shows a very 
distinct expression pattern in tumourigenesis and can act as negative regulator of cell 
proliferations by inducing apoptosis and thus inhibit cell proliferation in certain type 
of tumour cells (Blackhall et al., 2001, Capurro et al., 2005). Glypican-3 is not 
normally expressed in liver and colon but is upregulated in hepatocellular carcinoma 
and in colorectal cancer (Filmus 2008, Midorikawa et al., 2003, Ligato et al., 2008). It 
is worth to note that if the origin of the tumour is from a tissue that expresses 
glypican-3 only during the embryonic period, glypican-3 expression reappear during 
malignant transformation. If the origin of cancer is from glypican-3 positive tissue in 
adult, its expression is reduced in the tumour, which makes the tumour more invasive 
in nature (Filmus, 2008). 
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METHODS 
Glycosyltransferase assay 
 
Figure 6. The GlcA-TII and GlcNAc-TII reactions. 
The GlcA-TII assay measures the transfer of 14C GlcA unit from the corresponding 
UDP-sugar to the oligosaccharide acceptor (upper reactions) with a nonreducing end 
GlcNAc. The GlcNAc-TII assay instead measures the transfer of 14C GlcNAc unit 
from the corresponding UDP-sugar to oligosaccharide acceptor (lower reactions) with 
a non-reducing end GlcA.  
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PRESENT INVESTIGATIONS 
AIM OF THE STUDY 
The overall aim of this thesis was to study the role of EXTL1, EXTL2 and EXTL3 in 
HS biosynthesis. The thesis work has been divided into two subprojects; one dealing 
with EXTL2 (Paper I) and the other with EXTL1 and EXTL3 (Paper II). 
RESULTS 
Paper I  
The role of EXTL2 in heparan sulphate chain elongation 
In order to investigate if EXTL2 may have a function in mammalian HS biosynthesis, 
the effect of reduced or increased levels of human EXTL2 on HS chain elongation 
was analysed. Human embryonic kidney (HEK) 293 cells were transiently transfected 
with siRNA targeting EXTL2 in order to suppress EXTL2 expression or cells were 
transfected with a plasmid containing the full-length EXTL2 to increase its expression 
level. Downregulation of EXTL2 by siRNA resulted in an increased HS chain length, 
whereas cells overexpressing EXTL2 produced shorter HS chains as compared to 
untreated control cells. In addition, EXTL2 was able to catalyze the addition of a 
single GlcNAc to [GlcA-GlcNAc]n oligosaccharide acceptors (GlcNAc-TII activity), 
but did not show any detectable transfer of GlcA to GlcNAc[GlcA-GlcNAc]n
oligosaccharide acceptors (GlcA-TII activity). 
Paper II 
Effect of overexpression of EXTL1 on heparan sulphate chain length 
In this paper, HEK 293 cells were stably transfected with EXTL1 and EXTL3 and the 
effect of overexpression on HS chain elongation was studied. Overexpression of 
either EXTL1 or EXTL3 resulted increased chain length and an altered disaccharide 
composition. Cells overexpressing EXTL1 or EXTL3 produced HS chains with 
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decrease in IdoA2S-GlcNS and increase in GlcA-GlcNS6S disaccharide unit. To 
study the effect of down regulation of EXTL3 on HS chain elongation, HEK 293 cells 
were transiently transfected with siRNA targeting EXTL3. Similar to cells 
overexpressing EXTL3, cells silenced with siEXTL3 also synthesized longer HS 
chains. In addition, EXTL1 and EXTL3, showed identical in vitro enzyme activities 
with each other and with EXTL2 (paper I). They catalyzed the addition of a single 
GlcNAc to [GlcA-GlcNAc]n oligosaccharide acceptors (GlcNAc-TII activity), but 
showed no detectable transfer of GlcA to GlcNAc[GlcA-GlcNAc]n oligosaccharide 
acceptors (GlcA-TII activity). 
Figure 7. Effects of up or down regulation of EXTL1, EXTL2 or EXTL3 on 
heparan sulphate chain elongation. 
(A) Reduction in EXTL3 results in synthesis of longer HS chains. (B) Gene silencing 
of EXTL2 and overexpression of EXTL1 and EXTL3 produces HS chain that are 
longer than wild type cells. (C) EXTL2 overexpression results in shorter HS chains. 
+EXTL1 -EXTL2(B)
+Overexpression 
Downregulation 
 -EXTL3
+EXTL2
Wild cells
(A)
(C)
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DISCUSSION 
The mechanism that regulates the molecular diversity of HS is not fully understood 
and in particular we lack knowledge about the regulation and topography of the 
biosynthetic machinery involved in HS biosynthesis. HS has a unique molecular 
design and is a selective binding partner of several different proteins and is involved 
in many biological processes including embryonic development, differentiation, 
morphogen distribution and cell signalling. HS biosynthesis, which occurs in the 
Golgi apparatus, is a complex process involving many enzymes and enzyme isoforms. 
This process generates a non-sulphated polysaccharide chain that is modified by a 
sequential and coordinated series of enzyme reactions to form the mature HS chain. 
To understand HS-related biological functions that are dependent on the structural 
variability of HS we need to understand the function and regulation of enzymes 
involved in HS biosynthesis. HSPGs are an important feature of the cell surface and 
ECM. Both HS fine structure and chain length play important roles in determining the 
binding site for HS-dependent signalling factors and thus influence HS interaction 
with a variety of molecules (Lindahl et al., 1998, Österholm et al., 2009). The length 
of HS chains varies. Most chains contains between 50-200 disaccharide units (25-100 
kDa), and due to that HS chains form extended helical coil structures, this size range 
corresponds to 40-160 nm in length (Turnbull et al., 2001). The mechanism 
controlling HS chain elongation and chain termination is poorly understood. EXT1-
EXT2 is a heter-oligomeric complex that is necessary for HS chain elongation 
(McCormick et al., 2000, Senay et al., 2000, Busse and Kusche-Gullberg, 2003). The 
three EXTLs (EXTL1, EXTL2, EXTL3) share aminoacid sequence homology with 
EXT1 and EXT2 (Kitagawa et al., 1999, Kim et al., 2001) indicating that EXTLs 
could be involved in HS chain biosynthesis but, except for EXTL3, their involvement 
in HS biosynthesis is unclear. To clarify the respective function of EXTL1, EXTL2 
and EXTL3 in HS biosynthesis, the effect of reduced or increased levels of human 
EXTL1, EXTL2 and EXTL3 proteins in HEK 293 cells on HS chain elongation and 
HS fine structure was analyzed.  
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                    Previous results from our lab have shown that gene silencing of EXTL3 
produces longer HS chains (Busse et al., 2007). Our recent results are in consistent 
with the previous findings. In the paper by Busse et al. (Busse et al., 2007) it was 
speculated that EXTL3 was responsible for adding the first GlcNAc to the linkage 
region. With reduced amounts of EXTL3, fewer chains would be initiated but as the 
number of EXT1/EXT2 complex was not affected, this resulted in more extensive 
polymerisation (Busse et al., 2007). Mice deficient in EXTL3 die neonatally and lack 
HS further supporting the idea that EXTL3 is an initiator of HS synthesis (Takahashi 
et al., 2009). C. elegans mutants lacking rib-2 (C. elegans ortholog of EXTL3) has 
reduced production of HS (Morio et al., 2003). Mutation in box (the zebrafish 
ortholog of EXTL3) also shows a dramatic decrease in HS biosynthesis and the 
mutant phenotype can be rescued by injection of wild type box mRNA (Lee et al., 
2004). Our recent results, that overexpression of EXTL3 also resulted in longer chains 
(paper II) complicates the picture and indicates that EXTL3, in addition to initiate the 
chains, also influences chain elongation. It has been speculated that EXTL3 could be 
a terminator of chain elongation (Kim et al., 2001) but if this was the case, 
overexpressing EXTL3 should have resulted in shorter chains. Interestingly, removal 
of HS chains by heparitinase treatment upregulated Extl3 mRNA levels in mouse 
pancreatic β-cells, indicating a feed back mechanism where EXTL3 is regulating HS 
biosynthesis (Takahashi et al., 2009).  
                    EXTL2 has been shown to have only GlcNAc-TI activity and not 
GlcNAc-TII activity (Kitagawa et al., 2001) but here we show that it has GlcNAc-TII 
activity as well. This is very interesting and could indicate that EXTL3 and EXTL2 
have similar roles in HS synthesis. However, although siRNA of EXTL2 (Paper I), 
similar to corresponding treatment of EXTL3 (Paper II), resulted in synthesis of 
longer chains, overexpression of EXTL2, in contrast to similar treatment of EXTL3, 
resulted in synthesis of shorter chains, indicating that they may have different 
functions. Furthermore, in agreement with out results, transgenic mice overexpressing 
EXTL2 have reduced amount of HS (Nadanaka and Kitagawa, 2008). Okada et al. 
(Okada et al., 2010) speculated that in cells lacking EXT1, HS chains were initiated 
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by EXTL2 and polymerisation carried out by EXT2 (Okada et al., 2010). Synthesis of 
longer HS chain after siRNA could indicate that EXTL2 is a chain terminator or an 
inhibitor of HS elongation. This could also explain the finding that EXTL2 
overexpression results in shorter HS chains. siRNA of EXTL2 also resulted in 
increased HS/CS ratio but did not seem to influence the HS disaccharide composition. 
The changes in HS/CS ratio was observed both for 35S- and 3H-labelled material 
(Paper II and unpublished data, respectively) and could possibly indicate that there is 
a limited amount of UDP-GlcA in the Golgi lumen. With increased synthesis of HS 
the UDP-GlcA pool may be insufficient for both HS and CS synthesis. One important 
point to have in mind is that our values relate to cell surface/ECM associated PGs and 
may not reflect the total GAG production.  
                    Cells overexpressing EXTL1 produced longer chains with altered 
disaccharide structure. Increased levels of EXTL1 may have resulted in increase 
incorporation of GlcNAc residue on the growing HS chain and thus resulting in 
longer HS chains. As chain elongation in HS involves the action of EXT1 and EXT2 
to catalyze the transfer of GlcA and GlcNAc from their respective UDP-derivatives to 
the non-reducing end of growing polymer (Busse and Kusche-Gullberg, 2003) it may 
be speculated that EXTL1 can form a complex with EXT1 or EXT2 to perform this 
action. In this case, GlcA will be incorporated by EXT1 and/or EXT2. So a possibility 
of several different types of multimeric complex involved in HS chain elongation may 
exist. It has been questioned if EXTL1, because of its restricted tissue specific 
expression, is involved in HS chain elongation. Our results show, for the first time, 
that EXTL1 exhibited a significant GlcNAc-TII activity. In addition, increased chain 
length and an altered disaccharide composition after overexpression indicate that 
EXTL1 is involved in HS chain elongation. Because HEK 293 cells do not express 
EXTL1, we could not study the effect of gene silencing of EXTL1 on HS chain 
length. At the moment we do not know of any human cell line that expresses EXTL1. 
However, the mouse C2C12 myoblast cell line has been shown to dramatically 
upregulate Extl1 expression during C2C12 differentiation into myotubes (Janot et al., 
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2009). It would be highly interesting to study the effect on HS synthesis after down-
regulation of EXTL1 in differentiated C2C12 cells. 
                       Most if not all of the biosynthetic enzymes involved in HS biosynthesis 
have been cloned. However, we still know little about the organization of the 
biosynthetic apparatus or the localization of the enzymes in the Golgi membrane.  In 
addition, very little is known about how the biosynthetic enzymes interact with each 
other and with other proteins. The hypothetic “GAGosome” is a model to explain how 
the enzymes in the HS biosynthetic machinery cooperate and influence each other. 
The GAGosome is defined as a complex of different HS enzymes/or enzyme 
isoforms. In the GAGosome model, the relative amounts of each enzyme/enzyme 
isoform present in the GAGosome will have an impact on the HS structure. 
Complexes between different HS enzymes have been described, such as the 
EXT1/EXT2 complex (Kobayashi et al., 2000, McCormick et al., 2000, Senay et al., 
2000) and between the 2OST and the C5-epimerase (Pinhal et al., 2001, Smeds et al., 
2010). In a recent study, the authors speculate that the combined N-deacetylase/N-
sulfotransferase-1 (NDST1) and EXT1 compete for binding to EXT2, which acts as a 
transport protein for both enzymes from the endoplasmic reticulum to the Golgi 
(Presto et al., 2008). Our results in paper I and II, indicate that the at least EXTL1 and 
EXTL3 may assist EXT1 and/or EXT2 in the polymerization process in vivo, since 
overexpression of these proteins resulted in longer chains. However, if the EXTLs 
collaborate or form complexes with other proteins involved in HS biosynthesis is still 
an open question. 
                    Development of hereditary multiple osteochondromas is caused by 
mutations in either EXT1 or EXT2 and the resulting reduction, but not total loss, of 
HS in the chondrocytes of exostoses, suggests that exostoses formation is a result of 
reduced HS (Stickens et al., 2005). Contradictory reports are present on the cellular 
origin of the osteochondroma and, although tumour suppressor properties were early 
ascribed to EXT1 and EXT2, it remains unclear if EXT1 and EXT2 fit the classical 
two-hit model for tumour suppressor genes, which implies that osteochondroma 
results from a somatic mutation in the remaining wild-type copy of the gene 
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(Knudson, 1971). In a recent publication, mice with a clonal homozygous inactivation 
of Ext1 in chondrocytes developed frequent osteochondromas supporting the two-hit 
model for osteochondroma development (Jones et al., 2009). There is no evidence that 
defects in the EXTL genes or any other genes involved in HS biosynthesis result in 
exostoses formation suggesting that only the inactivation of EXT1 or EXT2 in a small 
fraction of chondrocytes result in the formation of osteochondromas. It is still an open 
question how exostoses formation due to defective EXT proteins relates to HS 
biosynthesis. 
                     In conclusion, our study revealed that HS chain length may be controlled 
by all three EXTLs and that changes in the EXTLs levels influence HS chain length. 
Still there are many questions that need to be addressed in future. Is it possible that, 
not only EXT1 and EXT2 elongate HS chains or does it exist several elongation 
complexes composed of different combinations of EXT/EXTLs? Is EXTL2 an 
inhibitor of chain elongation or does it have another function? What determines the 
length of an HS chain? Generation of mice that are deficient in one or more of the 
EXTLs can be helpful further to understand the role of EXTLs in HS biosynthesis. 
However, so far very little information has been generated regarding the individual 
roles of the EXTs in HS biosynthesis from mice deficient in EXT1, EXT2 or EXTL3. 
They die at an early embryonic stage and lack HS (Lin et al., 2000, Stickens et al., 
2005, Takahashi et al., 2009). The individual contribution of each EXTL could be 
investigated. For example it would be interesting to see whether EXTLs collaborate 
with one another or with EXT1 and/or EXT2. Alternatively, EXTLs can also form 
biological complex like EXT1 and EXT2 to polymerise HS chains. 
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